Rhythm Pharmaceuticals, Inc. RYTM
NASDAQ · United States · Health Technology
$95.57+0.35 (+0.37%)
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
-- First targeted therapy approved in Canada for patients four years and older living with acquired hypothalamic obesity (HO) --BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that Health Canada has approved IMCIVREE® (setmelanotide) for the additional indication of weight management in adult and pediat
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Stanley Druckenmiller’s Duquesne Family Office recently filed its 13F for the second quarter. The firm opened new stakes in more than 40 stocks. Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) and Definium Therapeutics, Inc. (NASDAQ:DFTX) are the notable ones in the healthcare space. Duquesne bought 203,618 shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) worth $22.6 million. The fund also […]
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.